Management ChangeMay 27, 2026, 04:13 PM
Zentalis Appoints Shannon Campbell to Board, Compensation Committee
AI Summary
Zentalis Pharmaceuticals, Inc. announced the appointment of Shannon Campbell to its Board of Directors, effective May 22, 2026. The Board's size increased from six to seven directors. Ms. Campbell will serve as a Class I director until the 2027 Annual Meeting and has also been appointed to the Compensation Committee. Her compensation includes an annual retainer of $45,000 for Board service and an additional $7,500 for committee service, along with an initial grant of 114,200 restricted stock units and future annual equity grants.
Key Highlights
- Zentalis Pharmaceuticals increased its Board size from six to seven directors.
- Shannon Campbell was appointed as a Class I director, with her term expiring at the 2027 Annual Meeting.
- Ms. Campbell was also appointed to the Board's Compensation Committee.
- She will receive an annual retainer of $45,000 for Board service.
- An additional annual retainer of $7,500 is provided for Compensation Committee service.
- Ms. Campbell was granted 114,200 restricted stock units (RSUs) vesting over three years.
- Annual equity grants will cover shares determined by multiplying outstanding shares by 0.08%.
- Equity awards vest in full upon a change in control, subject to continued service.
Price Impact
More from ZNTL